Thursday, January 18 2024 | 07 h 28 min | Vision Science
Stargardt disease is a rare genetic eye disease that happens when fatty material builds up on the macula. Vision loss usually starts in childhood — but some people with Stargardt disease don’t start to lose their vision until they’re adults
Belite Bio is testing an oral drug Tinlarebant (LBS-008) in a Phase 3 trial, to see if it slows progression of Stargardt disease. Tinlarebant is designed to lower levels of vitamin-A based toxins. The trial has completed enrollment and results are expected to be announced in 2024.